Valeant Pharma (VRX) Reports Q2 EPS of $1.91
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) reported Q2 EPS of $1.91, versus $1.34 reported last year. Revenue for the quarter came in at $1.99 billion, versus $1.06 billion reported last year.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Atlassian results seen as 'game changer' for AI kills software worries
- Minerva Neurosciences (NERV) Tops Q2 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
